Rybelsus®
Semaglutide (oral) · GLP-1 Tablet
First oral GLP-1 — daily tablet form of semaglutide for people who prefer no injections.
Rybelsus® is the first GLP-1 receptor agonist available as a daily tablet. It contains semaglutide — the same active ingredient as Ozempic® and Wegovy® — in an oral formulation. Licensed for type 2 diabetes, Rybelsus also reduces appetite and supports weight management as part of a clinician-supervised programme. A great option for patients who strongly prefer tablets over injections.
- Active ingredient
- Semaglutide 3 / 7 / 14 mg
- Format
- Oral tablet
- Frequency
- Once daily, fasting
- Prescription
- Required
Benefits
Why patients choose Rybelsus®.
No injections
First and only daily oral GLP-1 — ideal if you’re needle-averse.
Reduces appetite
Same GLP-1 mechanism that supports feeling fuller sooner between meals.
Metabolic support
Improves blood-sugar control and often body-weight alongside diet and activity.
Clinician reviewed
Our pharmacist checks suitability, other medicines and titration plan.
How it works
A simple, evidence-based approach.
- 1
Take one tablet first thing in the morning, at least 30 minutes before any food or drink.
- 2
Swallow whole with a small sip of plain water (no more than ~120 mL).
- 3
Semaglutide is absorbed through the stomach lining and activates GLP-1 receptors.
- 4
Start at 3 mg for 30 days, then step up to 7 mg and (if needed) 14 mg.
Choose your dose
Prescription-only medicine. Every order is reviewed by a UK-registered prescriber before dispatch.
Questions
Rybelsus® FAQs
Everything you need to know before starting your course.
Alternatives
